Exagen (XGN) Preferred Stock Liabilities (2018 - 2019)

Exagen's (XGN) quarterly Preferred Stock Liabilities came in at $121.0 million in Q2 2019, up 5.36% on a QoQ basis from $114.9 million in Q1 2019.

Exagen (XGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Exagen (XGN) has 2 years of Preferred Stock Liabilities data on file, last reported at $121.0 million in Q2 2019.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $121.0 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $121.0 million (changed N/A YoY) and the FY2018 annual result came in at $105.2 million, changed N/A from the prior year.
Preferred Stock Liabilities rose to $121.0 million in Q2 2019, from $114.9 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $121.0 million in Q2 2019 to a low of $102.4 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn	-
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn	-
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn	-
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn	-
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn	-
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn	-
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn	-
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn	-
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn	-
10	Exagen	158.28 Mn	133.68 Mn	12.22 Mn	-

Download Data